Abstract
Chordomas are relatively rare, slowly growing primary tumors of bone that arise from embryonic remnants of the notochord. These neoplasms typically occur in the axial skeleton mainly in the skull base (about 35%) and sacral region (about 50%) and have an overall peak distribution in patients aged 55-65 years. Chordomas are divided into conventional (the most common type), chondroid, and dedifferentiated types. Aggressive initial therapy, based on radical-maximal surgery followed by post-operative irradiation, improves overall outcome. Patients who relapse locally have a poor prognosis but both radiation and surgery can be used as salvage therapy. Radiation therapy alone may also be used in order to treat some patients with advanced, inoperable lesions or local recurrence. Proton beam irradiation has been reported as a very active form of irradiation for its peculiar physical properties. Chordomas are reported as tumors non sensitive to chemotherapy, even though anecdotal reports have been shown some sensitivity to molecularly targeted therapies.
Keywords: Chordoma, skull base, sacrum, radiotherapy, particle therapy
Current Drug Therapy
Title: Current Management of Chordoma
Volume: 5 Issue: 1
Author(s): Maurizio Amichetti and Dante Amelio
Affiliation:
Keywords: Chordoma, skull base, sacrum, radiotherapy, particle therapy
Abstract: Chordomas are relatively rare, slowly growing primary tumors of bone that arise from embryonic remnants of the notochord. These neoplasms typically occur in the axial skeleton mainly in the skull base (about 35%) and sacral region (about 50%) and have an overall peak distribution in patients aged 55-65 years. Chordomas are divided into conventional (the most common type), chondroid, and dedifferentiated types. Aggressive initial therapy, based on radical-maximal surgery followed by post-operative irradiation, improves overall outcome. Patients who relapse locally have a poor prognosis but both radiation and surgery can be used as salvage therapy. Radiation therapy alone may also be used in order to treat some patients with advanced, inoperable lesions or local recurrence. Proton beam irradiation has been reported as a very active form of irradiation for its peculiar physical properties. Chordomas are reported as tumors non sensitive to chemotherapy, even though anecdotal reports have been shown some sensitivity to molecularly targeted therapies.
Export Options
About this article
Cite this article as:
Amichetti Maurizio and Amelio Dante, Current Management of Chordoma, Current Drug Therapy 2010; 5 (1) . https://dx.doi.org/10.2174/1574885511005010001
DOI https://dx.doi.org/10.2174/1574885511005010001 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Translational Research of Photodynamic Therapy with Acridine Orange which Targets Cancer Acidity
Current Pharmaceutical Design Regulatory Influence of Scaffolds on Cell Behavior: How Cells Decode Biomaterials
Current Pharmaceutical Biotechnology Cancer Metastasis as Disrupted Developmental Phenotype
Current Genomics Anti-Angiogenic Therapies for Children with Cancer
Current Cancer Drug Targets Cells Under Pressure – Treatment of Eukaryotic Cells with High Hydrostatic Pressure, from Physiologic Aspects to Pressure Induced Cell Death
Current Medicinal Chemistry Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor
Current Respiratory Medicine Reviews Prepontine Chordoma Presenting with MRI Features of an Epidermoid Cyst: Case Presentation and a Mini-Review
Current Medical Imaging Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes
Current Cancer Drug Targets CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry The Key Role of Canonical Wnt/β-catenin Signaling in Cartilage Chondrocytes
Current Drug Targets Understanding Mesenchymal Cancer: The Liposarcoma-Associated t(12;16) (q13;;p11) Chromosomal Translocation as a Model
Current Genomics Synthesis and Biological Evaluation of Some Hydrazone Derivatives as Anti-inflammatory Agents
Letters in Drug Design & Discovery Histone Deacetylase Inhibitors: Recent Insights from Basic to Clinical Knowledge & Patenting of Anti-Cancer Actions
Recent Patents on Anti-Cancer Drug Discovery Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets Inflammatory Signaling in Cartilage: MAPK and NF-κ B Pathways in Chondrocytes and the Use of Inhibitors for Research into Pathogenesis and Therapy of Osteoarthritis
Current Drug Targets MicroRNA and Bone Tumor: To Up Date
Current Signal Transduction Therapy Peeking into the Black Box: How Cytokine Antibody Arrays Shed Light on Molecular Mechanisms of Breast Cancer Development and its Treatment
Current Proteomics Polyelectrolyte Multilayer Films: From Physico-Chemical Properties to the Control of Cellular Processes
Current Medicinal Chemistry MicroRNAs in the Intracellular Space, Regulation of Organelle Specific Pathways in Health and Disease
MicroRNA Anticancer Properties of Flavonoids: Roles in Various Stages of Carcinogenesis
Cardiovascular & Hematological Agents in Medicinal Chemistry